Gales A C, Sader H S, Jones R N
Division of Infectious Diseases, Universidade Federal de São Paulo, São Paulo, Brazil.
Clin Microbiol Infect. 2005 Feb;11(2):95-100. doi: 10.1111/j.1469-0691.2004.01051.x.
The activity of dalbavancin, a new semi-synthetic lipoglycopeptide antibiotic, was evaluated in comparison with other antibacterial agents against 1229 Gram-positive organisms collected from medical centres in Latin America. Dalbavancin was the most potent compound tested against isolates of Staphylococcus aureus (MIC(50), 0.06 mg/L) and coagulase-negative staphylococci (MIC(50), 0.03 mg/L), independently of methicillin susceptibility. Dalbavancin inhibited all Streptococcus pneumoniae isolates at </= 0.06 mg/L. Dalbavancin also demonstrated excellent activity against beta-haemolytic (MIC(50), </= 0.008 mg/L) and viridans group (MIC(50), 0.016 mg/L) streptococci. All vancomycin-susceptible Enterococcus spp. isolates were inhibited by dalbavancin at </= 0.25 mg/L, but some vancomycin-resistant Enterococcus spp. isolates were only inhibited by dalbavancin levels of >/= 8 mg/L. Dalbavancin exhibited excellent activity against isolates of Corynebacterium spp. and Listeria spp. Dalbavancin may provide an important therapeutic option for Gram-positive infections, excluding those caused by enterococci with VanA-type resistance.
将一种新型半合成脂糖肽抗生素达巴万星的活性与其他抗菌剂进行了比较，以评估其对从拉丁美洲医疗中心收集的1229株革兰氏阳性菌的抗菌活性。达巴万星是针对金黄色葡萄球菌分离株（MIC（50），0.06mg/L）和凝固酶阴性葡萄球菌（MIC（50），0.03mg/L）测试的最有效的化合物，与甲氧西林敏感性无关。达巴万星在≤0.06mg/L时可抑制所有肺炎链球菌分离株。达巴万星对β溶血性链球菌（MIC（50），≤0.008mg/L）和草绿色链球菌（MIC（50），0.016mg/L）也表现出优异的活性。所有对万古霉素敏感的肠球菌属分离株在≤0.25mg/L时被达巴万星抑制，但一些对万古霉素耐药的肠球菌属分离株仅在≥8mg/L的达巴万星水平下被抑制。达巴万星对棒状杆菌属和李斯特菌属分离株表现出优异的活性。达巴万星可能为革兰氏阳性菌感染提供一种重要的治疗选择，但不包括由VanA型耐药肠球菌引起的感染。
